What does the Nobel Prize have to do with cancer research in Oslo Cancer Cluster?
This year the Nobel Prize for Physiology and Medicine was awarded to James P. Allison and Tasuku Honjo for their work on unleashing the body’s immune system to attack cancer. This was a breakthrough that has led to an entirely new class of drugs and brought lasting remissions to many patients who had run out of options.
A statement from the Nobel committee hailed the accomplishments of Allison and Honjo as establishing “an entirely new principle for cancer therapy.”
This principle, the idea behind much of the immunotherapy we see developing today, is shared by several of our Oslo Cancer Cluster members, including Oslo University Hospital and the biotech start-up Zelluna.
– This year’s Nobel Price winners have contributed to giving new forms of immunotherapy treatments to patients, resulting in improved treatments to cancer types that previously had poor treatment alternatives, especially in combination with other cancer therapies, said doctor Else Marit Inderberg as a comment to the price.
She leads the immunomonitoring unit of the Department of Cellular Therapy at Oslo University Hospital. The unit is present in Oslo Cancer Cluster Incubator with a translational research lab.
Inderberg has been studying and working with T-cells since 1999, first within allergies and astma, before she was drawn to cancer research and new cancer therapies in 2001.
So, what is a T-cell?
T-cells have the capacity to kill cancer cells. These T-cells are a subtype of white blood cells and play a central role in cell-mediated immunity. They are deployed to fight infections and cancer, but malignant cells can elude them by taking advantage of a switch – a molecule – on the T-cell called an immune checkpoint. Cancer cells can lock onto those checkpoints, crippling the T-cells and preventing them from fighting the disease.
The drugs based on the work of Nobel Prize winners Allison and Honjo belong to a class called checkpoint inhibitors – the same immune checkpoint that we find on T-cells. Drugs known as checkpoint inhibitors can physically block the checkpoint, which frees the immune system to attack the cancer.
– We work on other ways of activating the immune system, but in several clinical trials we combine cancer vaccines or other therapies with the immune-modulating antibody, the checkpoint inhibitors, which the Nobel Price winners developed, Inderberg explained.
Inderberg and her team of researchers in the translational research lab in Oslo Cancer Cluster Incubator use the results from the Nobel Price winners’ research in their own research in order to develop their own therapy and learn more about the mechanisms behind the immune cells’ attack on the cancer cells and the cancer cells’ defence against the immune system.
– This Nobel Prize is very inspiring for the entire field and it contributes to making this kind of research more visible, Else Marit Inderberg added.
– Our challenge now is to make new forms of cancer therapies available for a large number of patients and find ways to identify patient groups who can truly benefit from new therapies – and not patients who will not benefit. Immunotherapy also has some side effects, and it is important that we keep working on these aspects of the therapy as well.
From research to company
Most of the activity of the translational research lab in Oslo relies on the use of a database of patient samples called the biobank. This specific biobank represents an inestimable source of information about the patients’ response to immunological treatments over the years. Furthermore, the patient material can be reanalysed and therapeutic molecules isolated. This is the basis of the Oslo Cancer Cluster member start-up company Zelluna.
Want to know more about Zelluna and the research they are spun out of?